A Case Report of Retroperitoneal Seminoma and Literature Review

Chiumento Costanza1*, Fiorentino Alba1, Tartarone Alfredo2, Lapadula Loredana1, Caivano Rocchina1, Cozzolino Mariella1 and Vincenzo Fusco1

1Department of Radiation Oncology, I. R. C. C. S. - C. R. O. B. Padre Pio Street 1, 85028 Rionero in Vulture (Pz), Italy
2Department of Medical Oncology, I. R. C. C. S. - C. R. O. B. Padre Pio Street 1, 85028 Rionero in Vulture (Pz), Italy

Abstract

Aims and background: Extra-gonadal germ cell tumours (EGCT) are rare tumors, which usually occur in the mediastinum or retroperitoneum; in particular, primary retroperitoneal seminomas account for approximately 2% of all seminomas. We report the case of a 34-year-old male with a locally advanced retroperitoneal seminoma.

Methods: The patient underwent debulking surgery followed by cisplatin-based chemotherapy and radiotherapy.

Results: No evidence of recurrence was detected during a 30 months follow-up. Although retroperitoneal seminoma is rare, this entity should be considered in the differential diagnosis of a male patient presenting with a mass in the retroperitoneum.

Conclusions: Our case, according to data reported in literature, confirms the curability of retroperitoneal seminoma even in presence of bulky disease, and it represents an example of revised treatment procedure due to patient’s particular condition.

Keywords: Retroperitoneal seminoma; Testicular involvement; Radiotherapy

Introduction

Germ cells tumours in men usually arise from testes, only 1-2% originating from other locations [1].

The extra-gonadal germ cell tumours (EGCT) are rare, accounting for 0.15-0.2% of all malignancies and representing approximately 5% of all germ cells tumour (GCTs) [2].

EGCT mostly affect young men and develop from germ cells precursors that become arrested during embryological migration and colonize ectopic sites. The anatomic distribution of EGCT is varied and includes the mediastinum, sacrococcygeal region, neck, retro-peritoneum and other rare sites. However, retro-peritoneum represents the second most common extra-gonadal site after mediastinum.

These tumours are predominantly non-seminomatous in histology, occur frequently in patient with Klinefelter’s syndrome and are frequently associated with the development of haematological malignancies [3,4].

EGCT produce a wide variety of symptoms and may reach large volumes if they arise in silent areas. In this report, we present a case of retroperitoneal seminoma.

Case Report

A 34-year-old Caucasian male, presented to the emergency department with left upper abdominal pain, nausea, fatigue and abdominal distension. The patient has a genetic malformation dysmorphic syndrome consisting in ptosis, diastasis of the abdomen rectum muscles, hip dysplasia and undescended right testis. Physical examination of left testis was normal. Tumoral markers (β- HCG and alpha fetoprotein) and LDH levels were within normal limits. Abdominal ultrasound showed a 8×5 cm left retroperitoneal mass, extending to left kidney without hydronephrosis.

A testicular ultrasound evidenced a small left testicle size with multiple hypoechoic nodules and right undescended testicle.

A subsequent CT scan confirmed the presence of a retroperitoneal mass suggestive of a primary tumour (Figure 1).

Then the patient underwent a CT-guided biopsy, that permitted a diagnosis of classical seminoma with immunohistochemical positive reaction of neoplastic cells to placental alkaline phosphatase (PLAP) (Figure 2).

On June 2010, due to the worsening of the clinical condition, the patient underwent extensive resection of the retroperitoneal mass plus lymphadenectomy, left nephrectomy and removal of the undescended right testis.

The definitive diagnosis was seminoma arising from retroperitoneal
space with atrophy of the right testis and without infiltration of left kidney and adrenal gland.

A CT scan performed after surgery showed a residual retroperitoneal mass of 2.6x1.5 cm (Figure 3).

From September to November 2010 the patient received three cycles of cisplatin-based chemotherapy (PEB regimen: cisplatin 20 mg/m² on days 1-5, etoposide 100 mg/m² on days 1-5, bleomycin 30 U on days 2, 9, and 16, every 3 weeks). Patient completed chemotherapy otherwise he experienced acute haematological toxicity (neutropenia G3) that required the use of hematopoietic growth factors (G-CSF). A post-chemotherapy CT scan didn’t show any residual mass.

From January to February 2011 the patient received radiotherapy. In particular, a 3D-Conformal Radiotherapy (3D-CRT), with nominal energy of 15 MV was administered with a total dose of 25.2 Gy (1.8 Gy/day). Clinical target volume (CTV) was surgical bed plus para-aortic lymphonodes and ipsilateral pelvic nodes, Planned Target Volume (PTV) was CTV plus margins. During 3D-CRT acute gastrointestinal toxicity G2 (measured with RTOG Toxicity Scale) was recorded.

At last follow-up, on December 2012 a CT body scan revealed no recurrence disease in mediastinum and retroperitoneum space (Figure 4).

Discussion

Retroperitoneum represents the most likely site for secondary lesions, including metastatic lymphadenopathy from occult tumour, and primary tumours such as lymphoma, liposarcoma, teratoma etc. Retroperitoneal seminoma is a rare disease. Often it's difficult for clinicians distinguish primary germ cells tumour to metastatic lesion specially for seminoma, which tend to spread by lymphatic channel to retroperitoneal lymph nodes.

Previous reports in literature described a "burned out" phenomenon of germ cells tumours, consisting in extragonadal germ cell tumour with no evidence of neoplasm at the testis level [5-9].

The burned-out testicular tumour shows a distinctive constellation of findings that usually permits its recognition. A careful sonographic scrotal examination can reveal some abnormalities (echogenic foci, microlithiasis, scar formation and inhomogeneity) suggesting a regressed testicular tumour [10].

These ultrasonic features are nonspecific thus a ipsilateral inguinal orchietomy is mandatory to confirm a disappeared testicle tumour throught a series of distinctive histological lesions (testicular atrophy, nodular scar etc.) and to reduce probability of persistent testicular cancer [11]. More recently, Gurioli et al. [12] confirmed the important role of testicular ultrasonography in patients presenting CT of retroperitoneal mass, even if patients are completely asymptomatic and their physical examination appears normal.

In our case it was not possible to analyze hystologically the left testis because the patient refused left orchiectomy.

Treatment of EGCT requires a combination of therapies: surgery, cisplatin-based chemotherapy and radiotherapy [6,13,14].

Seminomas tumours are very sensitive to chemotherapy and radiotherapy. Nichols [15] recommends primary abdominal radiotherapy for patients with small volume retroperitoneal seminomas (abdominal mass <5 cm) and chemotherapy for patients with larger volume disease. The prognosis is excellent in cases of seminomatous histology with 5-years survival rates>90% achieved with platinum-based chemotherapy. Furthermore, cisplatin-based chemotherapy reduces the risk of metachronous contralateral testicular germ cell tumour (TGCT), with cumulative incidence for patients with unilateral TGCT is 1-5% [16,17].

In our case due to the worsening of the clinical condition, the patient underwent debulking surgery followed by cisplatin-based chemotherapy and radiotherapy.

There are few cases reported in literature regarding patients with
retroperitoneal seminoma. These studies showed favourable outcomes both for short and long follow-up periods with combined modality treatment approach and revealing the higher frequency of metastatic retroperitoneal tumours from primary unevolved testicular tumour [5,18-23] (Table 1).

The association of germ cell tumours (GCTs) with gonadal dysgenesis is well known [24]. According to literature, our patient has been grouped within the "Testicular Dysgenesis Syndrome" only for the presence of right cryptorchidism. The histological examination of right testis revealed atrophy without signs of dysgenesis. It was not possible to investigate on the left testis because of patient refused biopsy or orchectomy. The patient has a dysmorphic syndrome consisting in ptosis, diastasis of the abdomen rectum muscles, hip dysplasia and undescended right testis. A PCR analysis of FMR-1 (locus FRAXA) was detected in all family members. After a preliminary analysis was not identified yet a gene related to his dysmorphic syndrome and the genetic evaluation is still in progress.

One of the current areas of attention for pathologists and oncologists is the improvement of diagnostics for CIS (or intratubular germ cell neoplasia unclassified or testicular intraepithelial neoplasia) which occurred upon on third of patients with retroperitoneal and mediastinal GCTs [25-27].

Recent data have provided potential diagnostic tools including CIS detection in semen and novel stem cell markers for immunohistochemical diagnosis of gonadal and extragonadal GCTs, these methods may become applicable for screening or as an auxiliary test that allow a careful follow-up [28,29].

Conclusion

GCTs are a very interesting tumors entity with specific biological and clinical characteristics. Although retroperitoneal seminoma is rare, this entity should be considered in the differential diagnosis of a male patient presenting with a mass in the retroperitoneum. Our case confirms the curability of retroperitoneal seminoma even in presence of bulky disease. However the increase knowledge about immunohistochemistry of GCTs and the research of novel histological markers, could adopted a new global perspective about investigation and treatment of these tumours.

References


Table 1: A comparison of similar published case of retroperitoneal seminoma and outcomes.

<table>
<thead>
<tr>
<th>Authors name (year of publication)</th>
<th>N of pts</th>
<th>Retroperitoneal mass size</th>
<th>Testicular ultrasound alterations</th>
<th>Tumour markers</th>
<th>Ipsilateral Orchiectomy</th>
<th>Types of treatment</th>
<th>Follow-up</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abell (1965) [19]</td>
<td>10</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>3/10</td>
<td>RT alone; S+RT</td>
<td>29 months</td>
<td>NED</td>
</tr>
<tr>
<td>Bookmayer (2001) [20]</td>
<td>52</td>
<td>7 cm</td>
<td>NR</td>
<td>AFP normal, βHCG, LDH high</td>
<td>NR</td>
<td>CHT; RT alone; CHT+RT</td>
<td>49 months</td>
<td>5-year OS 88%</td>
</tr>
<tr>
<td>Perimenis P (2005) [22]</td>
<td>1</td>
<td>4 cm</td>
<td>Normal</td>
<td>Yes</td>
<td>Yes</td>
<td>S+ RT</td>
<td>24 months</td>
<td>NED</td>
</tr>
<tr>
<td>Kontos S (2009) [23]</td>
<td>1</td>
<td>7 cm</td>
<td>Yes</td>
<td>Normal</td>
<td>Yes</td>
<td>S+ CHT</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Sachin Malde (2010) [24]</td>
<td>1</td>
<td>12 cm</td>
<td>No</td>
<td>Normal</td>
<td>No</td>
<td>CHT</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Preda O. (2011) [25]</td>
<td>1</td>
<td>NR</td>
<td>Yes</td>
<td>AFP, βHCG normal LDH high</td>
<td>Yes</td>
<td>S+ CHT</td>
<td>5 months</td>
<td>NED</td>
</tr>
</tbody>
</table>

NR: Non reported; AFP: Alpha feto protein; β HCG: Human chorionic gonadotropin beta; LDH: Lactate dehydrogenase; RT: Radiotheraphy; CHT: Chemiotherapy; S: Surgery; OS: Overall Survival; NED: Non evidence disease


Submit your next manuscript and get advantages of OMICS Group submissions

Unique features:
- User friendly/feasible website-translation of your paper to 50 world’s leading languages
- Audio Version of published paper
- Digital articles to share and explore

Special features:
- 250 Open Access Journals
- 20,000 editorial team
- 31 days rapid review process
- Quality and quick editorial, review and publication processing
- Indexing at PubMed (partial), Scopus, EBSCO, Index Copernicus and Google Scholar etc
- Sharing Option: Social Networking enabled
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscript at: www.editorialmanager.com/biochem